BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18077981)

  • 1. Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions.
    Zendehrokh N; Rehnberg J; Dejmek A
    Acta Cytol; 2007; 51(6):886-92. PubMed ID: 18077981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
    Zendehrokh N; Dejmek A
    Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
    Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
    Adell E; Dejmek A
    Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
    Nieh S; Chen SF; Fu E; Jan CI; Lee WH
    Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
    Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer.
    Cha N; Li XY; Zhao YJ; Wang EH; Wu GP
    Clin Lung Cancer; 2012 Nov; 13(6):494-9. PubMed ID: 22464057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical localization of hTERT protein in human tissues.
    Yan P; Benhattar J; Seelentag W; Stehle JC; Bosman FT
    Histochem Cell Biol; 2004 May; 121(5):391-7. PubMed ID: 15138842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ telomerase activity in pleural effusions: a promising marker for malignancy.
    Dejmek A; Yahata N; Ohyashiki K; Ebihara Y; Kakihana M; Hirano T; Kawate N; Kato H
    Diagn Cytopathol; 2001 Jan; 24(1):11-5. PubMed ID: 11135462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity.
    Wright WE; Shay JW; Piatyszek MA
    Nucleic Acids Res; 1995 Sep; 23(18):3794-5. PubMed ID: 7479015
    [No Abstract]   [Full Text] [Related]  

  • 12. Telomerase activity and hTERT mRNA expression in body fluids.
    Yamamoto Y; Hirakawa E
    Diagn Cytopathol; 2005 Mar; 32(3):167-70. PubMed ID: 15690332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
    Nagel H; Schlott T; Schulz GM; Droese M
    Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity in benign and malignant cytologic fluids.
    Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
    Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
    Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expressions of human telomerase mRNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNA in effusion cytology.
    Hiroi S; Nakanishi K; Kawai T
    Diagn Cytopathol; 2003 Oct; 29(4):212-6. PubMed ID: 14506674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profile of telomerase subunits in human pleural mesothelioma.
    Dhaene K; Wauters J; Weyn B; Timmermans JP; van Marck E
    J Pathol; 2000 Jan; 190(1):80-5. PubMed ID: 10640996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity.
    Wege H; Chui MS; Le HT; Tran JM; Zern MA
    Nucleic Acids Res; 2003 Jan; 31(2):E3-3. PubMed ID: 12527792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours.
    Schneider-Stock R; Boltze C; Jäger V; Epplen J; Landt O; Peters B; Rys J; Roessner A
    J Pathol; 2003 Apr; 199(4):517-25. PubMed ID: 12635143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues.
    Yano Y; Yoshida K; Osaki A; Toge T; Tahara H; Ide T; Yasui W
    Anticancer Res; 2002; 22(6C):4101-7. PubMed ID: 12553039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.